In December 2015, US company ZZ Biotech LLC completed the acquisition of Bioatrix Pty Ltd. Based in Houston, ZZ Biotech is in a Phase 2 trial with 3K3A-Activated Protein C (‘3K3A-APC’) in acute ischemic stroke patients, supported by a grant from the National Institute for Neurological Disease and Stroke.

ZZ Biotech’s Australian subsidiary is presently manufacturing 3K3A-APC at Patheon Biologics in Brisbane and it has secured Queensland Government grant funding to facilitate the manufacture.

The Australian subsidiary will pursue a Phase 2 trial with 3K3A-APC in chronic wounds in 2016, and ZZ Biotech will undertake further trials of 3K3A-APC in stroke.